Sells medicines, vaccines and other products to prevent and treat disease in pets and farm animals, serving veterinarians, pet owners, farmers and animal producers.
10-K for FY2025, filed Feb 24, 2026Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal…View ↗
Pet Health: Our pet health products help pets live longer, healthier and more active lives. Our global pet health portfolio is focused on…View ↗
Farm Animal: Our farm animal products help producers improve animal health and wellbeing and raise livestock more sustainably, delivering…View ↗
Elanco primarily sells products to customers, generally getting paid when goods ship and the customer takes title. It also earns revenue from contract manufacturing and royalties; manufacturing revenue may come as work is performed or when goods or services are delivered, while royalties are tied to underlying sales.
10-K for FY2025, filed Feb 24, 2026
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗$4.7B
10-K for FY2025, filed Feb 24, 2026
$4.7B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Pet Health
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
49%
FY2022: 48%
|
Pet Health, FY2025
$2.3B Sources
|
Sold outright |
|
Farm Animal:
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
50%
FY2022: 50%
|
Farm Animal:, FY2025
$2.4B Sources
|
Sold outright |
|
Contract Manufacturing and Other
Mix
|
1.1%
FY2022: 1.2%
|
Contract Manufacturing and Other, FY2025
$53M Sources
|
Mix |
Pet health products mainly go to distributors and retailers, and directly to veterinarians, who typically resell them to pet owners. Farm animal products go through distributors and directly to producers, including beef, dairy, pork and poultry operations.
10-K for FY2025, filed Feb 24, 2026We primarily sell our pet health products to third-party distributors and retailers, as well as directly to veterinarians who typically…View ↗
10-K for FY2025, filed Feb 24, 2026
We have a single customer that accounted for approximately 12%, 11% and 10% of revenue for the years ended December 31, 2025, 2024 and…View ↗
Not on paper. It lost $232M in FY2025, but brought in more cash than it spent: $284M of free cash flow.
10-Q for Q3 FY2026, filed Nov 6, 2026
$18MView ↗
10-Q for Q3 FY2026, filed Nov 6, 2026
Open tableView ↗
Flat. Revenue was $4.7B in FY2025, about the same as the $4.8B of FY2021.
Competes with Zoetis, Boehringer Ingelheim Animal Health GmbH, and Merck Animal Health
10-K for FY2025, filed Feb 24, 2026Our primary competitors include animal health medicines and vaccines companies such as Zoetis Inc., Boehringer Ingelheim Animal Health…View ↗
Loading...